Subtype
Female Reproductive System Neoplasm
CI-CAN-00000885Explore in graph →
Non-malignant1,633 active trials11 approved drugs139 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000885Explore in graph →
Clinical trials
7,174 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04576104 | Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer | active not recruiting | Phase 2 | 51 | Northwestern UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05357027 | HPV16 E6 TCR T Cells for Cervical Carcinoma | terminated | Phase 1 / Phase 2 | 5 | TCRCure Biopharma Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer |
| recruiting |
| Phase 2 |
| 96 |
| Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY |
| 1 |
| Jan 21, 2026 |
| clinicaltrials |
| NCT07355010 | A Randomized, Open-label, Double-cohort Study of Fluzoparib Combined With Famitinib Malate or SHR-1701 for Neoadjuvant Therapy in Patients With Advanced Ovarian Cancer | not yet recruiting | Phase 2 | 104 | Qinglei GaoOTHER | 0 | Jan 21, 2026 | clinicaltrials |
| NCT07348861 | A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer | not yet recruiting | Phase 2 | 25 | Zheng MinOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT04876456 | A Phase II Trial of Cabozantinib With Patients With Refractory GCTs | active not recruiting | Phase 2 | 50 | Jennifer KingOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07340489 | Serplulimab for Locally Advanced Cervical Cancer | recruiting | Phase 2 | 216 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06238635 | Dostarlimab and Cobolimab in Advanced Cervical Cancer | active not recruiting | Phase 2 | 66 | Meghan SheaOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT04260802 | A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | terminated | Phase 1 / Phase 2 | 73 | Ocellaris Pharma, Inc.INDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06536517 | The Effects of One-time Intraoperative Methadone During Laparoscopic Hysterectomy in Reducing Opioid Prescription. | recruiting | Phase 2 | 100 | Johns Hopkins UniversityOTHER | 1 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05041257 | Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers(PICCOLO) | completed | Phase 2 | 79 | AbbVieINDUSTRY | 7 | Jan 9, 2026 | clinicaltrials |
| NCT05082025 | Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | terminated | Phase 2 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05481645 | Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus. | terminated | Phase 2 | 71 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06478862 | Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy | terminated | Phase 2 | 19 | Lipomedix Pharmaceuticals Inc.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT06562166 | Online Adaptive Radiotherapy for Cervical Cancer | recruiting | Phase 2 | 124 | Peking Union Medical College HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05504252 | METIMMOX-2: Metastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxaliplatin(METIMMOX-2) | active not recruiting | Phase 2 | 80 | University Hospital, AkershusOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06173037 | RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer | completed | Phase 2 | 43 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | recruiting | Phase 2 | 25 | Panagiotis Konstantinopoulos, MD, PhDOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06545617 | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Thera SolutionsINDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT06727617 | Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors | recruiting | Phase 2 | 134 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07080216 | Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 120 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Jan 5, 2026 | clinicaltrials |
| NCT06416696 | Toripalimab for High-risk Locally Advanced Cervical Cancer | active not recruiting | Phase 2 | 57 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT04141449 | A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation(Potlako+) | active not recruiting | Phase 2 | 874 | Brigham and Women's HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06463028 | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | recruiting | Phase 2 | 40 | Faeth TherapeuticsINDUSTRY | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06640283 | Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes(ANA) | recruiting | Phase 2 | 150 | Instituto do Cancer do Estado de São PauloOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06690775 | CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 230 | TORL Biotherapeutics, LLCINDUSTRY | 12 | Dec 23, 2025 | clinicaltrials |
| NCT07298642 | Extended-field Proton Therapy for Cervical Cancer | recruiting | Phase 2 / Phase 3 | 44 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06971744 | Autophagy Maintenance (AUTOMAIN) | recruiting | Phase 2 | 38 | Medical University of South CarolinaOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07108270 | A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) | recruiting | Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT02001272 | EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer(EWOC-1) | completed | Phase 2 | 120 | Hospices Civils de LyonOTHER | 6 | Dec 19, 2025 | clinicaltrials |
| NCT03959761 | Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma(ICONIC) | completed | Phase 1 / Phase 2 | 22 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07261683 | Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer | recruiting | Phase 2 | 20 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07295132 | RESCUE Study (REcurrent Ovarian Cancer Secondary Cytoreduction Using Chemotherapy rEsponse) | not yet recruiting | Phase 2 | 160 | Asan Medical CenterOTHER | 0 | Dec 19, 2025 | clinicaltrials |
| NCT07167160 | Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial | recruiting | Phase 2 | 59 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT06682572 | A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients(RAMP201J) | active not recruiting | Phase 2 | 16 | Verastem, Inc.INDUSTRY | 1 | Dec 17, 2025 | clinicaltrials |
| NCT05001347 | A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors | completed | Phase 2 | 25 | I-Mab Biopharma US LimitedINDUSTRY | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05296512 | Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer | active not recruiting | Phase 2 | 30 | Elizabeth K. Lee MDOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT07285941 | Efficacy and Safety of Distamab Vedotin Combined With Carboplatin for Advanced Ovarian Cancer in the First Line Treatment | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05454358 | Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP | terminated | Phase 2 / Phase 3 | 12 | Fudan UniversityOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer | terminated | Phase 2 | 17 | Mayo ClinicOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04339140 | Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer | completed | Phase 2 | 5 | Beth Israel Deaconess Medical CenterOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT07273396 | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for Platinum-resistant Recurrent Ovarian Cancer | not yet recruiting | Phase 1 / Phase 2 | 53 | Seoul National University HospitalOTHER | 0 | Dec 9, 2025 | clinicaltrials |
| NCT05106127 | Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem | not yet recruiting | Phase 2 | 28 | Evergreen Therapeutics, Inc.INDUSTRY | 0 | Dec 8, 2025 | clinicaltrials |
| NCT03249142 | Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer(INeOV) | completed | Phase 1 / Phase 2 | 69 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 21, 2026source: clinicaltrials